Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  
Top Ad

Find Out

How to Find One Stock with Crorepati Potential? >> READ MORE

  • Home
  • Views On News
  • May 19, 2022 - Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend

May 19, 2022

Pharma major Dr Reddy's Lab today reported its March quarter results during market hours.

Concerns regarding cost pressures were mounting for the past couple of months, so investors were keen to know how the pharma company's profit margins were impacted.

Dr Reddy's has a huge exposure to Russia, and CIS regions. The company has the highest export exposure to these regions, among domestic drugmakers.

Though the company doesn't have any manufacturing plant in Russia, it has had a presence in the region for over three decades. Revenue from Russia accounts for about 8-10% of the company's total revenue.

Here are four key takeaways from Dr Reddy's March quarter results.

  • Dr Reddy's consolidated net profit for the quarter ended March 2022 dropped to Rs 875 m, compared with Rs 3.6 bn in the same quarter last year. This translates into a 75.6% drop.
  • The company's revenues rose to Rs 54.4 bn, a growth of 15% YoY and 2% on a sequential basis.
  • During the quarter, there were significant changes to the market conditions of the products forming part of Dr Reddy's generics and proprietary products segments.

    The changes include decrease in the market potential of products, increased competition leading to lower volumes, and revenues not being in line with projections.
  • Dr Reddy's board recommended a final dividend of Rs 30 per share (600% on face value).

Dr Reddy's Lab share price opened the day at Rs 3,850 against its previous close of Rs 3,908.

As soon as it declared results, shares saw a sudden spike and rose over 1% to Rs 3,949.

Interestingly, Dr Reddy's Lab and ITC were the only gainers today from the pack of BSE 30 stocks. Even as stock markets continue to fall, both these stocks traded in green.

The reason behind ITC's outperformance is that ITC's results beat estimates, which sent the stock to its 52-week high.

Coming back to Dr Reddy's performance...

So far this year, shares of Dr Reddy's Lab have underperformed the markets and have lost over 25%.

About Dr Reddy's Lab

Dr Reddy's Lab is a leading India-based pharmaceutical company headquartered and having its registered office in Hyderabad, Telangana, India.

The company has key presence is in India, North America, Russia and CIS countries, Europe and other emerging markets. The company has wide portfolio in several markets and has made several niche and Para IV launches.

For more details about the company, you can have a look at Dr Reddy's fact sheet and Dr Reddy's quarterly results on our website.

For a sector overview, you can read our pharma sector report.

You can also compare Dr Reddy's Lab with its peers on our website.

Dr Reddy's Lab vs Aurobindo Pharma

Dr Reddy's Lab vs Cipla

Dr Reddy's Lab vs Sun Pharma

Dr Reddy's Lab vs Abbott India

Dr Reddy's Lab vs Divi's Lab

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...

Equitymaster requests your view! Post a comment on "Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend". Click here!


More Views on News

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

More Views on News

Most Popular

4 Sectors to Watch for Future Multibagger Stocks (Views On News)

Jun 17, 2022

With India's economic recovery accelerating, these sectors are likely to give multibagger returns in the future.

Why Tata Power Share Price is Falling (Views On News)

Jun 14, 2022

Here's why shares of Tata Power have fallen in recent days.

Is it Time to Start Buying Stocks Selectively? (Profit Hunter)

Jun 16, 2022

Some sectors have corrected by 50%. Do they merit a look?

Best Monopoly Stocks to Own in 2022 Views On News (Views On News)

Jun 18, 2022

Constant product innovation, latest technology, strong supply chain etc can all help companies enjoy monopoly like fortunes.

When Will the Stock Market Recover? (Views On News)

Jun 15, 2022

This is how you can tell the market is going to recover.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Jun 24, 2022 (Close)


  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks